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ﬂurazepam, zolpidem or zaleplon, trazadone, and diphenhy-
dramine) commonly used to treat individuals with a complaint
of insomnia. Patient level weights were utilized to derive US
national population estimates. Given the complex stratiﬁed
survey design, Rao Scott and Wald Chi-square tests were used
to assess statistically signiﬁcant differences within groups.
RESULTS: For all patients taking a medication commonly used
to treat sleep complaints, psychiatrists were more likely to pre-
scribe trazadone (54%), while family/general practice physicians
(29%), general internists (35%) and other specialists (28) were
more likely to prescribe zolpidem or zaleplon. Those 65 years
and older were more likely to be prescribed zolpidem or zale-
plon (30%) and younger patients were most often prescribed
trazadone (70%). CONCLUSION: Newer sleep agents such as
zolpidem or zaleplon are the most commonly prescribed med-
ication across the majority of physician-types. This study pro-
vides an important descriptive look at those who are taking
medications commonly used to treat sleep disorders.
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DETERMINE THE PREVALENCE OF INSOMNIA IN 
FOUR COUNTRIES
Edmondson M,Annunziata K
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To utilize international patient reported outcomes
(PROs) data and identify the size and impact of patient popula-
tions suffering from insomnia/sleep difﬁculty in four countries:
United States, UK, France, and Germany. METHODS: An
annual, self-reported study of consumer attitudes and behaviors
conducted by Consumer Health Sciences was ﬁelded in June,
2004 and completed by 60,050 adults, 18 years of age or older
in the United States (40,736), UK (8393), France (9011), and
Germany (9064). We stratiﬁed and weighted the sample by key
demographics. All respondents were asked if they experienced
insomnia or sleep difﬁculty within the past 12-months and if they
had their condition physician diagnosed. Respondents also com-
pleted the SF-8 and the WPAI. RESULTS: Of the 374.0 million
adults in the four countries examined, 27% (101.8 million)
reported to have experienced insomnia/sleep difﬁculty in the pre-
vious 12-months. The number of insomnia/sleep difﬁculty suf-
ferers in the United States is 53.2 million, 51% of total number
of sufferers, while the number of insomnia/sleep difﬁcult suffer-
ers in the UK, France and Germany combined is 48.6 million
adults, 49% of total number of sufferers. Diagnosed insom-
nia/sleep difﬁculty sufferers in the UK have the lowest SF-8
Mental health score: 39.2 and the lowest SF-8 Physical health
score: 37.9 (p < 0.05). The percentage of insomnia/sleep difﬁ-
culty sufferers who missed work due to their health 26% or 
more of the time was highest in France: 25.5% and lowest 
in the United States: 12.7% (p < 0.05). CONCLUSIONS: 
Insomnia/sleep difﬁculty remains a signiﬁcant health care issue
for adults in the United States, UK, France and Germany. The
impact that insomnia/sleep difﬁculty has on the quality of life
and productivity of adults warrants further investigation for
public policy makers and health care ofﬁcials.
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OBJECTIVE: To understand the hemoglobin (Hb) thresholds
Pulmonologists (PULs) use to assess anemia severity in COPD.
METHODS: A survey was conducted to identify Hb thresholds
representing presence and severity of anemia in COPD.
RESULTS: One hundred PULs completed the survey at a spe-
cialty society meeting in 2004. All were either board-certiﬁed or
eligible in Pulmonary Medicine. Forty-seven percent have been
in practice for <5 years, with 30% and 23% in practice for 5–15
years and >15 years, respectively. The vast majority (86%) see
almost exclusively adult patients, 41% of the responders follow
<250 patients, while 41% see 250–1000 and 12% see >1000
patients with lung disease. Responders estimated that COPD
accounts for 49% of their lung disease patients, followed by
asthma (24%), lung cancer (13%) and obstructive sleep apnea
(13%). Only 21% of the PULs considered anemia to be Hb £
12g/dL. Furthermore, 37% of the responders considered Hb £
10g/dL to represent only mild anemia. Hb £ 9g/dL was identi-
ﬁed by 47% to represent moderate anemia, while Hb £ 8g/dL
was deemed to represent severe anemia by 75% of the respon-
ders. CONCLUSIONS: Despite the accepted WHO deﬁnition of
anemia (men, Hb < 13g/dL; women, Hb < 12g/dL), the major-
ity of PULs surveyed do not consider anemia to be present in
COPD patients until the Hb is <11g/dL, and a substantial
number consider a Hb < 10g/dL as only mild anemia. Results of
this survey suggest that PULs may not recognize mild anemia
which could lead to severe anemia and other complications.
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The characteristics of Chronic Obstructive Pulmonary Disease
(COPD) patients and the patterns of treatment have not been
well characterized in primary care settings. Determining how
drug treatment patterns align with COPD diagnosis and sever-
ity may help optimize care. OBJECTIVE: This study was
designed to explore treatment patterns at the time of and post
COPD diagnosis. METHODS: A national electronic medical
record database was queried to identify patients with at least six-
months history prior to a diagnosis of COPD (ICD-9 codes
491.xx, 492.xx, and 496). Pulmonary function test (PFT) results
closest to the ﬁrst diagnosis of COPD were evaluated to charac-
terize disease severity using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria. Prescription data
were evaluated at the time of diagnosis. All descriptive statistics
were conducted using STATA statistical software. RESULTS: A
total of 14,691 patients had COPD and six-months of data. Pre-
scription data at diagnosis were available for 9334 (64%) of
these patients. Of these, over 50% (n = 5264) had a prescription
on the date of diagnosis. The average number of days between
diagnosis and the ﬁrst prescription was 106 (SD+256.4). The
beta-adrenergic class was the most commonly prescribed therapy
(64%) post diagnosis. Only 273 (2%) of the 14,691 COPD
patients had PFT data adequate to determine the GOLD sever-
ity class. For this group, the average time from diagnosis to ﬁrst
prescription was inversely related to severity: 163 (SD+288.2)
days for Stage one and 124 (SD+152.3) days for Stage four.
CONCLUSIONS: COPD is often not diagnosed or treated until
the later stages of the disease, nor is PFT used routinely to diag-
nose, stage or guide treatment decisions. COPD severity seems
to inﬂuence the time between the date of diagnosis and physi-
cian prescription order.
